0.00Open0.00Pre Close0 Volume0 Open Interest22.50Strike Price0.00Turnover726.36%IV-55.71%PremiumOct 18, 2024Expiry Date8.05Intrinsic Value100Multiplier1DDays to Expiry0.00Extrinsic Value100Contract SizeAmericanOptions Type-0.7728Delta0.0460Gamma1.65Leverage Ratio-0.6350Theta-0.0007Rho-1.28Eff Leverage0.0027Vega
Alto Neuroscience Stock Discussion
Core business and technology:
Personalized Medication: Alto Neuroscience’s goa...
NEWS
Alto Neuroscience Announces Positive Phase 1 Results for ALTO-101, a Novel PDE4 Inhibitor in Development for Schizophrenia
ALTO-101 demonstrated favorable pharmacokinetic and tolerability profile in Phase 1 study
Transdermal formulation provided significantly greater drug exposure with fewer adverse events
Proof-of-concept study for CIAS to start in the first half of 2024
Topline data expected in the second half of 2025
Achievement of target exposure with propri...
No comment yet